AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

Seitz, Anna Katharina; Thoene, Silvia; Bietenbeck, Andreas; Nawroth, Roman; Tauber, Robert; Thalgott, Mark; Schmid, Sebastian; Secci, Ramona; Retz, Margitta; Gschwend, Jürgen E.; Ruland, Jürgen; Winter, Christof; Heck, Matthias

doi:10.1016/j.eururo.2017.07.024

Cited by 87 publications

(50 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AR-V7 is one of these candidates as a putative predictor of benefit to the newer ARS inhibitors, as demonstrated in several single-center trials and a recent meta-analysis, as discussed above 31,32,34,38,40 . These studies demonstrate in aggregate that the benefit of ARS inhibitors is limited to AR-V7(−) patients and very few patients with AR-V7(+) disease demonstrate benefit with abiraterone or enzalutamide.…”

Section: Potential Tools For Treatment Selectionmentioning

confidence: 95%

Section: Biomarkers In Metastatic Prostate Cancermentioning

confidence: 99%

“…For example, two recent studies correlated AR-V7 mRNA detection in the whole blood with clinical outcomes in patients with mCRPC treated with abiraterone or enzalutamide 38,39 . The first study, using semi-quantitative mRNA analysis of AR-V7 using analog PCR in peripheral whole blood of 85 men demonstrated worse outcome in patients with high-AR-V7 expression levels, including no PSA 50 responses, shorter PFS and OS 38 . The second study assessed AR-V7 (and PSA) mRNA levels in the whole blood of mCRPC patients using a highly-quantitative digital droplet PCR (ddPCR) methodology, and observed potential prognostic value of both tests on survival of patients treated with ASR inhibitors 39 .…”

Section: Biomarkers In Metastatic Prostate Cancermentioning

confidence: 99%

See 2 more Smart Citations

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer

Bastos

Antonarakis

2018

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

Section: Potential Tools For Treatment Selectionmentioning

confidence: 95%

Section: Biomarkers In Metastatic Prostate Cancermentioning

confidence: 99%

Section: Biomarkers In Metastatic Prostate Cancermentioning

confidence: 99%

See 1 more Smart Citation

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer

Bastos

Antonarakis

2018

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

show abstract

“…In a recent study, high levels of AR-V7 mRNA in blood were detectable in 15 out of 85 metastatic CRPC patients, none of which achieved a PSA response. Furthermore, high levels of cell-free AR-V7 mRNA levels were associated with (i) shorter PSA-PFS, (ii) shorter clinical PFS, and (iii) shorter OS [316]. …”

Section: Utility Of Cfdna In Clinical Oncologymentioning

confidence: 99%

The emerging role of cell-free DNA as a molecular marker for cancer management

Bronkhorst

Ungerer

Holdenrieder

2019

Biomolecular Detection and Quantification

451

375

View full text Add to dashboard Cite

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and monitoring. However, harnessing the full potential of cfDNA requires (i) the optimization and standardization of preanalytical steps, (ii) refinement of current analysis strategies, and, perhaps most importantly, (iii) significant improvements in our understanding of its origin, physical properties, and dynamics in circulation. The latter knowledge is crucial for interpreting the associations between changes in the baseline characteristics of cfDNA and the clinical manifestations of cancer. In this review we explore recent advancements and highlight the current gaps in our knowledge concerning each point of contact between cfDNA analysis and the different stages of cancer management.

show abstract

“…Although these drugs represent breakthroughs for the treatment of CRPC, approximately 20–40% of patients have no response to these agents . AR‐V7 is associated with resistance to enzalutamide and abiraterone in metastatic CRPC patients, and many researchers are focusing on the possibility of AR‐V7 as a biomarker . Recently, Del et al .…”

Section: Therapeutic Strategies For Urological Cancer Using Evsmentioning

confidence: 99%

Extracellular vesicles: Toward a clinical application in urological cancer treatment

Urabe

Kosaka²,

Kimura

et al. 2018

Int J of Urology

View full text Add to dashboard Cite

Extracellular vesicles are nanometer-sized lipid membranous vesicles that are released from almost all types of cells into the extracellular space. Extracellular vesicles have gained considerable attention in the past decade, and emerging evidence suggests that they play novel roles in mediating cancer biology. Extracellular vesicles contain pathogenic components, such as proteins, DNA fragments, messenger ribonucleic acids, non-coding ribonucleic acids and lipids, all of which mediate paracrine signaling in the tumor microenvironment. Extracellular vesicles impact the multistep process of cancer progression through modulation of the immune system, angiogenesis and pre-metastatic niche formation through transfer of their contents. Therefore, a better understanding of their roles in urological cancers will provide opportunities for novel therapeutic strategies. In addition, the contents of extracellular vesicles hold promise for the discovery of liquid-based biomarkers for prostate, kidney and bladder cancers. Here, we summarize the current research regarding extracellular vesicles in urological cancer and discuss potential clinical applications for extracellular vesicles in urological cancer.

show abstract

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

Cited by 87 publications

References 26 publications

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer

The emerging role of cell-free DNA as a molecular marker for cancer management

Extracellular vesicles: Toward a clinical application in urological cancer treatment

Contact Info

Product

Resources

About